Comparison between intensified neoadjuvant treatment and standard preoperative chemoradiation for rectal cancer

Tumori

Volumn 96, Issue 1, 2010, Pages 11-16

  Musio, Daniela ^a   Raffetto, Nicola ^a   Dionisi, Francesco ^a   Iannacone, Eva ^a   Dipalma, Bartolomeo ^a   Caparrotti, Francesca ^a   Meaglia, Ilaria ^a   Caiazzo, Rossella ^a   Bangrazi, Caterina ^a   Banelli, Enzo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Continuous 5 fluoruracil infusion; Oxaliplatin; Preoperative radiochemotherapy; Rectal cancer

Indexed keywords

ANTIEMETIC AGENT; FLUOROURACIL; OXALIPLATIN; STEROID;

ADJUVANT THERAPY; ADULT; AGED; ANASTOMOSIS LEAKAGE; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONTROL GROUP; DERMATITIS; DIARRHEA; DRUG FATALITY; DRUG INFUSION; FEMALE; FISTULA; HEART INFARCTION; HUMAN; MALE; NEUROPATHY; PATIENT MONITORING; PELVIS PAIN SYNDROME; PREOPERATIVE PERIOD; PROCTITIS; RECTUM CANCER; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; VALIDATION STUDY; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DIARRHEA; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PELVIC PAIN; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 77950803584     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089161009600102     Document Type: Article

References (31)

1. Heald RJ, Ryall RD: Recurrence and survival after total mesorectal excision for rectal cancer. Lancet, 327: 1479-1482, 1986.
2. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, Van Krieken JH, Leer JW, Van de Velde CJ: Dutch Colorectal Cancer Group: Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med, 345: 638-646, 2001. (Pubitemid 34066236)
3. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic- Jelic L, Daban A, Bardet E, Beny A, Ollier JC, for EORTC Radiotherapy Group Trial 22921: Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med, 355: 1114-1123, 2006.
4. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R, for the German Rectal Cancer Study Group: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Eng J Med, 351: 1731-1741, 2004.
5. O'Connell MJ, Martenson JA, Wieand HS, Krook JE, Macdonald JS, Haller DG, Mayer RJ, Gunderson LL, Rich TA: Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med, 331: 502-507, 1994. (Pubitemid 24984711)
6. Kim JS, Kim JS, Cho MJ, Song KS, Yoon WH: Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys, 54: 403-408, 2002.
7. Corvò R, Pastrone I, Scolaro T, Marcenaro M, Berretta L, Chiara S: Radiotherapy and oral capecitabine in the preoperative treatment of patients with rectal cancer: rationale, preliminary results and perspectives. Tumori, 89: 361-367, 2003. (Pubitemid 37279915)
8. Blackstock AW, Hess S, Chaney S, Tepper JE: Oxaliplatin: in vitro evidence of its radiosensitizing activity. Preclinical observations relevant to clinical trials. Int J Radiat Oncol Biol Phys, 45: 253-254, 1999.
9. Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events, Version 3.0 (http://ctep.cancer.gov), Publish Date: August 9, 2006.
10. Klautke G, Fietkau R: Intensified neoadjuvant radiochemotherapy for locally advanced rectal cancer: a review. Int J Colorectal Dis, 22: 457-465, 2007. (Pubitemid 46488049)
11. Harris M: Monoclonal antibodies as therapeutic agents for rectal cancer. Lancet Oncol, 5: 292-302, 2004. (Pubitemid 38541581)
12. Kosmas C, Kallistratos MS, Kopterides P, Syrios J, Skopelitis H, Mylonakis N, Karabelis A, Tsavaris N: Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol, 134: 75-82, 2008. (Pubitemid 350060687)
13. Keam SJ, Dunn CJ, Figgitt DP: Oxaliplatin: in operable rectal cancer. Drugs, 65: 89-96, 2005.
14. Chau I, Brown G, Cunningham D, Tait D, Wotherspoon A, Norman AR, Tebbutt N, Hill M, Ross PJ, Massey A, Oates J: Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor risk rectal cancer. J Clin Oncol, 24: 668-673, 2006. (Pubitemid 46630432)
15. Schaffzin DM, Wong WD: Endorectal ultrasound in the preoperative evaluation of rectal cancer. Clin Colorectal Cancer, 4: 124-132, 2004. (Pubitemid 39199252)
16. MERCURY Study Group: Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BMJ, 333: 779-782, 2006. (Pubitemid 44583356)
17. Kuo LJ, Liu MC, Jian JJ, Horng CF, Cheng TI, Chen CM, Fang WT, Chung YL: Is final TNM staging a predictor for survival in locally advanced rectal cancer after preoperative chemoradiation therapy? Ann Surg Oncol, 14: 2766-2772, 2007.
18. Biondo S, Navarro M, Marti-Rague J, Arriola E, Pares D, Del Rio C, Cambray M, Novell V: Response to neoadjuvant therapy for rectal cancer: influence on long-term results. Colorectal Dis, 7: 472-479, 2005. (Pubitemid 41223142)
19. Kaminsky-Forrett MC, Conroy T, Luporsi E, Peiffert D, Lapeyre M, Boissel P, Guillemin F, Bey P: Prognostic implications of downstaging following preoperative radiation therapy for operable T3-T4 rectal cancer. Int J Radiat Oncol Biol Phys, 42: 935-941, 1998. (Pubitemid 29004132)
20. Valentini V, Coco C, Picciocchi A, Morganti AG, Trodella L, Ciabattoni A, Cellini F, Barbaro B, Cogliandolo S, Nuzzo G,Doglietto GB, Ambesi-Impiombato F, Cosimelli M: Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients. Int J Radiat Oncol Biol Phys, 53: 664-674, 2002. (Pubitemid 34626505)
21. Rödel C, Liersch T, Hermann RM, Arnold D, Reese T, Hipp M, Fürst A, Schwella N, Bieker M, Hellmich G, Ewald H, Haier J, Lordick F, Flentje M, Sülberg H, Hohenberger W, Sauer R: Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol, 25: 110-117, 2007. (Pubitemid 350003058)
22. Alonso V, Salud A, Escudero P, Valencia J, Mira M, Ruiz de Lobera A, Lambea J, Grandez R, Tres A, Anton A: Preoperative chemoradiation with oxaliplatin and 5-fluorouracil in locally advanced rectal carcinoma. J Clin Oncol (Meeting Abstracts), 22: abstr 3607, 2004.
23. Machiels JP, Duck L, Honhon B, Coster B, Coche JC, Scalliet P, Humblet Y, Aydin S, Kerger J, Remouchamps V, Canon JL, Van Maele P, Gilbeau L, Laurent S, Kirkove C, Octave- Prignot M, Baurain JF, Kartheuser A, Sempoux C: Phase II study of preoperative oxaliplatin, capecitabine and external beam radiation in patient with rectal cancer: the RadioOxCape study. Ann Oncol, 16: 1898-1905, 2005. (Pubitemid 41724278)
24. Moore HG, Gittleman AE, Minsky BD, Wong D, Paty PB, Weiser M, Temple L, Saltz L, Shia J, Guillem JG: Rate of pathological complete response with increased interval between preoperative combined modality therapy and rectal cancer resection. Dis Colon Rectum, 47: 279-286, 2004. (Pubitemid 38280578)
25. Tran CL, Udani S, Holt A, Arnell T, Kumar R, Stamos MJ: Evaluation of safety of increased time interval between chemoradiation and resection for rectal cancer. Am J Surg, 192: 873-877, 2006. (Pubitemid 44856719)
26. García-Aguilar J, Hernandez de Anda E, Sirivongs P, Lee SH, Madoff RD, Rothenberger DA: A pathological complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patients treated by mesorectal excision. Dis Colon Rectum, 46: 298-304, 2003. (Pubitemid 36331646)
27. Stipa F, Chessin DB, Shia J, Paty PB, Weiser M, Temple LK, Minsky BD, Wong WD, Guillem JG: A pathologic complete response of rectal cancer to preoperative combined-modality therapy results in improved oncological outcome compared with those who achieve no downstaging on the basis of preoperative endorectal ultrasonography. Ann Surg Oncol, 13: 1047-1053, 2006. (Pubitemid 44337963)
28. Capirci C, Valentini V, Cionini L, De Paoli A, Rodel C, Glynne-Jones R, Coco C, Romano M, Mantello G, Palazzi S, Osti MF, Friso ML, Genovesi D, Vidali C, Gambacorta MA, Buffoli A, Lupatteli M, Favretto MS, La Torre G: Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys, 72: 99-107, 2008.
29. Aschele C, Friso ML, Pucciarelli S, Lonardi S, Sartor L, Fabris G, Urso ED, Del Bianco P, Sotti G, Lise M, Monfardini S: A phase I-II study of weekly oxaliplatin, 5-fluoruracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer. Ann Oncol, 16: 1140-1146, 2005. (Pubitemid 41418317)
30. Ryan DP, Niedzwiecki D, Hollis D, Mediema BE, Wadler S, Tepper JE, Goldberg RM, Mayer RJ: Phase I-II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukaemia Group B 89901: J Clin Oncol, 24: 2557-2562, 2006. (Pubitemid 46630634)
31. Cionini L, Aschele C, Boni L, Laliscia T, Grandinetti A, Scotti V, Romeo S, Silvano G, Sainato A: A multicentric randomidized trial (STAR 01) comparing 5-fluorouracil alone (5-FU) vs 5-fluorouracil + oxaliplatin (5-FU-OXA), concomitant to pelvic radiotherapy (RT) as preoperative treatment in locally advanced rectal cancer: interim report on the first 313 patients. I Supplementi di Tumori, 7 (1), S59, 2008.